Skip to Content

Egrifta Side Effects

Generic Name: tesamorelin

Note: This document contains side effect information about tesamorelin. Some of the dosage forms listed on this page may not apply to the brand name Egrifta.

In Summary

Common side effects of Egrifta include: injection site reaction, erythema at injection site, bruising at injection site, irritation at injection site, and pain at injection site. Other side effects include: limb pain, myalgia, peripheral edema, and decreased glucose tolerance. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to tesamorelin: subcutaneous powder for solution

Along with its needed effects, tesamorelin (the active ingredient contained in Egrifta) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking tesamorelin:

More common
  • Difficulty with moving
  • muscle pain or stiffness
  • pain in the arms or legs
  • pain in the joints
Less common
  • Blurred vision
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • burning, numbness, pain, or tingling in all fingers except the smallest finger
  • chest pain
  • dizziness
  • fast, irregular, pounding, or racing heartbeat or pulse
  • headache
  • nervousness
  • pounding in the ears
  • slow or fast heartbeat
  • swelling of the joints
  • unsteadiness or awkwardness
  • weakness in the arms, hands, legs, or feet

Some side effects of tesamorelin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common
  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at injection site
  • muscle aching or cramping
Less common
  • Acid or sour stomach
  • belching
  • bone pain
  • discouragement
  • feeling of warmth
  • feeling sad or empty
  • heartburn
  • indigestion
  • irritability
  • itching skin
  • lack of appetite
  • loss of interest or pleasure
  • muscle spasms
  • nausea
  • night sweats
  • rash
  • redness of the face, neck, arms, and occasionally, upper chest
  • sleeplessness
  • stiffness of the joints
  • stomach discomfort, upset, or pain
  • strain in the muscles
  • sudden sweating
  • tiredness
  • trouble concentrating
  • trouble sleeping
  • unable to sleep
  • upper abdominal or stomach pain
  • vomiting

For Healthcare Professionals

Applies to tesamorelin: subcutaneous powder for injection


Very common (10% or more): Arthralgia (13.3%)
Common (1% to 10%): Pain in extremity, myalgia, musculoskeletal pain, musculoskeletal stiffness, joint stiffness, muscle spasms, joint swelling, muscle strain[Ref]


Common (1% to 10%): Injection site erythema, injection site pruritus, injection site pain, injection site irritation, injection site hemorrhage, injection site urticaria, injection site swelling, injection site reaction, injection site rash[Ref]

Nervous system

Common (1% to 10%): Paresthesia, hypoesthesia, carpal tunnel syndrome, peripheral neuropathy[Ref]


Common (1% to 10%): Nausea, vomiting, dyspepsia, abdominal pain upper[Ref]


Common (1% to 10%): Diabetes
Uncommon (0.1% to 1%): Increased HbA1c[Ref]


Common (1% to 10%): Palpitations, hypertension, hot flush[Ref]


Common (1% to 10%): Depression, insomnia[Ref]


Common (1% to 10%): Rash, pruritus, night sweats[Ref]


Common (1% to 10%): Peripheral edema, pain, chest pain, blood creatine phosphokinase increased


Very common (10% or more): Anti- tesamorelin (the active ingredient contained in Egrifta) IgG antibodies (49.5%)


1. "Product Information. Egrifta (tesamorelin)." Theratechnologies Inc., Montreal, ON.

Some side effects of Egrifta may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.